Ann: Increased Scheme Consideration from Pfizer, page-203

"It seems commercially naive to be looking at a sale of a Business Entity with out a full independent 3rd party valuation which includes the IP Suite"

Well now there is one. ResApp have the draft Independent Expert's Report already. It values the company at somewhere between 14.6c and 27.7c per share, or in other words at 21c ± 30%. At this point we have no idea of what the basis is of the valuation; whether IP is in or out, which markets were considered, what share of each market is estimated, the success-probability weighting, or anything.

ResApp must release the report with the scheme booklet for the takeover. There's nothing to say they couldn't release it earlier, independently of the takeover. It would be a valuable document for we shareholders in deciding how to vote on the takeover, and also for any potential competing bidder who could use the report as their first-pass due diligence.

For this reason I don't expect the board to release the report until they must, as doing so could represent a break of the implementation deed.